mRNA-2416
Phase 2Terminated 0 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer
Conditions
Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer
Trial Timeline
Aug 15, 2017 → Aug 18, 2021
NCT ID
NCT03323398About mRNA-2416
mRNA-2416 is a phase 2 stage product being developed by Moderna for Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03323398. Target conditions include Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03323398 | Phase 2 | Terminated |
Competing Products
20 competing products in Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer